FDA Expands Use of Breast Cancer Rx
For the first time in its history, the US Food and Drug Administration has approved a medication for the pre-surgical (neoadjuvant) treatment of early-stage (I, II) breast cancer.
New Drug for HER2-Positive Breast Cancer
The US Food and Drug Administration has approved a new drug to treat HER2-positive late-stage (metastatic) breast cancer. The drug has been shown to extend remission by about six months.